BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 31503338)

  • 1. Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting.
    Santos PMG; Barsky AR; Hwang WT; Deville C; Wang X; Both S; Bekelman JE; Christodouleas JP; Vapiwala N
    Cancer; 2019 Dec; 125(23):4278-4293. PubMed ID: 31503338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
    Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
    Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
    Dutz A; Agolli L; Baumann M; Troost EGC; Krause M; Hölscher T; Löck S
    Acta Oncol; 2019 Jun; 58(6):916-925. PubMed ID: 30882264
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients.
    Vapiwala N; Wong JK; Handorf E; Paly J; Grewal A; Tendulkar R; Godfrey D; Carpenter D; Mendenhall NP; Henderson RH; Stish BJ; Vargas C; Salama JK; Davis BJ; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1082-1089. PubMed ID: 33539968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer.
    Lukez A; Handorf E; Mendenhall NP; Henderson RH; Stish BJ; Davis BJ; Hallman M; Horwitz EM; Vapiwala N; Wong JK
    Prostate; 2024 Mar; 84(4):395-402. PubMed ID: 38108113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
    Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
    Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.
    Michalski JM; Yan Y; Watkins-Bruner D; Bosch WR; Winter K; Galvin JM; Bahary JP; Morton GC; Parliament MB; Sandler HM
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):932-8. PubMed ID: 24113055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
    Yu JB; DeStephano DM; Jeffers B; Horowitz DP; Soulos PR; Gross CP; Cheng SK
    J Clin Oncol; 2024 Jun; 42(16):1943-1952. PubMed ID: 38507655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon.
    Deville C; Both S; Bui V; Hwang WT; Tan KS; Schaer M; Tochner Z; Vapiwala N
    Radiat Oncol; 2012 May; 7():76. PubMed ID: 22621764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.
    Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.
    Akthar AS; Liao C; Eggener SE; Liauw SL
    Eur Urol; 2019 Nov; 76(5):686-692. PubMed ID: 31113644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Proton Beam Therapy in the Management of Thymoma: A Dosimetric Comparison and Acute Toxicities.
    Parikh RR; Rhome R; Hug E; Tsai H; Cahlon O; Chon B; Goenka A
    Clin Lung Cancer; 2016 Sep; 17(5):362-366. PubMed ID: 27372386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Analysis of 5-Year Clinical Outcomes and Patterns of Failure of Proton Beam Therapy Versus Intensity Modulated Radiation therapy for Prostate Cancer in the Postoperative Setting.
    Barsky AR; Carmona R; Verma V; Santos PMG; Both S; Bekelman JE; Christodouleas JP; Vapiwala N; Deville C
    Pract Radiat Oncol; 2021; 11(2):e195-e202. PubMed ID: 33242634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis.
    Teh BS; Mai WY; Uhl BM; Augspurger ME; Grant WH; Lu HH; Woo SY; Carpenter LS; Chiu JK; Butler EB
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):705-12. PubMed ID: 11172952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
    Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ
    Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
    Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
    BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.